Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials
Lindsay A. Renfro, Daniel J. Sargent
Daniel J. Sargent & Qian Shi: Statistics in Oncology Clinical Trials Column
Statistical aspect of translational and correlative studies in clinical trials
Herbert Pang, Xiaofei Wang
Phase III design: principles
Marc Buyse
Phase II design: history and evolution
Larry Rubinstein
Adaptive clinical trial designs in oncology
Yong Zang, J. Jack Lee
Biomarker based clinical trial design
Richard Simon
On independent data monitoring committees in oncology clinical trials
Janet Wittes, Mark Schactman
Overview: biostatistician’s role in oncology clinical trials—strive for sound, efficient and practical studies
Qian Shi, Daniel J. Sargent
The current design of oncology phase I clinical trials: progressing from algorithms to statistical models
Thomas M. Braun
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
Lindsay A. Renfro, Christina M. Coughlin, Axel M. Grothey, Daniel J. Sargent
| 1 - 10 of 10 Items |
Disclosure:
The series “Statistics in Oncology Clinical Trials” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Daniel J. Sargent and Qian Shi served as the unpaid Guest Editors for the series.